Profile of bazedoxifene/conjugated estrogens for the treatment of estrogen deficiency symptoms and osteoporosis in women at risk of fracture

References

• Chahal HS Drake WM The endocrine system and ageing J Pathol 2007 211 2 173 180 17200939
   PubMed Web of Science ®Google Scholar
• Vagenakis AG Endocrine aspects of menopause Clin Rheumatol 1989 8 Suppl 2 48 51 2667871
   PubMedGoogle Scholar
• Rödström K Bengtsson C Lissner L Milsom I Sundh V Björkelund C A longitudinal study of the treatment of hot flushes: the population study of women in Gothenburg during a quarter of a century Menopause 2002 9 3 156 161 11973438
   PubMed Web of Science ®Google Scholar
• Feldman BM Voda A Gronseth E The prevalence of hot flash and associated variables among perimenopausal women Res Nurs Health 1985 8 3 261 268 3852361
   PubMed Web of Science ®Google Scholar
• Versi E Harvey MA Cardozo L Brincat M Studd JW Urogenital prolapse and atrophy at menopause: a prevalence study Int Urogynecol J Pelvic Floor Dysfunct 2001 12 2 107 110 11374507
   PubMed Web of Science ®Google Scholar
• Haines CJ Xing SM Park KH Holinka CF Ausmanas MK Prevalence of menopausal symptoms in different ethnic groups of Asian women and responsiveness to therapy with three doses of conjugated estrogens/medroxyprogesterone acetate: the Pan-Asia Menopause (PAM) study Maturitas 2005 52 3–4 264 276 15921865
   PubMed Web of Science ®Google Scholar
• Bjarnason NH Alexandersen P Christiansen C Number of years since menopause: spontaneous bone loss is dependent but response to hormone replacement therapy is independent Bone 2002 30 4 637 642 11934658
   PubMed Web of Science ®Google Scholar
• Nilas L Christiansen C The pathophysiology of peri- and postmenopausal bone loss Br J Obstet Gynaecol 1989 96 5 580 587 2503028
   PubMedGoogle Scholar
• Cauley JA Seeley DG Ensrud K Ettinger B Black D Cummings SR Estrogen replacement therapy and fractures in older women. Study of Osteoporotic Fractures Research Group Ann Intern Med 1995 122 1 9 16 7985914
   PubMed Web of Science ®Google Scholar
• Khosla S Update on estrogens and the skeleton J Clin Endocrinol Metab 2010 95 8 3569 3577 20685883
   PubMed Web of Science ®Google Scholar
• Marx RE Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic J Oral Maxillofac Surg 2003 61 9 1115 1117 12966493
   PubMed Web of Science ®Google Scholar
• Park-Wyllie LY Mamdani MM Juurlink DN Bisphosphonate use and the risk of subtrochanteric or femoral shaft fractures in older women JAMA 2011 305 8 783 789 21343577
   PubMed Web of Science ®Google Scholar
• Parente L Uyehara C Larsen W Whitcomb B Farley J Long-term impact of the women’s health initiative on HRT Arch Gynecol Obstet 2008 277 3 219 224 17713777
   PubMed Web of Science ®Google Scholar
• Rossouw JE Anderson GL Prentice RL Writing Group for the Women’s Health Initiative Investigators Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women’s Health Initiative randomized controlled trial JAMA 2002 288 3 321 333 12117397
   PubMed Web of Science ®Google Scholar
• Komm BS Lyttle CR Developing a SERM: stringent preclinical selection criteria leading to an acceptable candidate (WAY-140424) for clinical evaluation Ann N Y Acad Sci 2001 949 317 326 11795370
   PubMed Web of Science ®Google Scholar
• Evista® (raloxifene hydrochloride) tablet [prescribing information] Indianapolis Eli Lilly and Company 2007
   Google Scholar
• Taylor HS Designing the ideal selective estrogen receptor modulator – an achievable goal? Menopause 2009 16 3 609 615 19182697
   PubMed Web of Science ®Google Scholar
• Komm BS A new approach to menopausal therapy: the tissue selective estrogen complex Reprod Sci 2008 15 10 984 992 19088368
   PubMed Web of Science ®Google Scholar
• Deroo BJ Korach KS Estrogen receptors and human disease J Clin Invest 2006 116 3 561 570 16511588
   PubMed Web of Science ®Google Scholar
• Komm BS Kharode YP Bodine PV Harris HA Miller CP Lyttle CR Bazedoxifene acetate: a selective estrogen receptor modulator with improved selectivity Endocrinology 2005 146 9 3999 4008 15961563
   PubMed Web of Science ®Google Scholar
• Crabtree JS Peano BJ Zhang X Komm BS Winneker RC Harris HA Activity of three selective estrogen receptor modulators on hormone-dependent responses in the mouse uterus and mammary gland Mol Cell Endocrinol 2008 287 1–2 40 46 18367319
   PubMed Web of Science ®Google Scholar
• Kharode Y Bodine PV Miller CP Lyttle CR Komm BS The pairing of a selective estrogen receptor modulator, bazedoxifene, with conjugated estrogens as a new paradigm for the treatment of menopausal symptoms and osteoporosis prevention Endocrinology 2008 149 12 6084 6091 18703623
   PubMed Web of Science ®Google Scholar
• Peano BJ Crabtree JS Komm BS Winneker RC Harris HA Effects of various selective estrogen receptor modulators with or without conjugated estrogens on mouse mammary gland Endocrinology 2009 150 4 1897 1903 19022889
   PubMed Web of Science ®Google Scholar
• Hall JM McDonnell DP Coregulators in nuclear estrogen receptor action: from concept to therapeutic targeting Mol Interv 2005 5 6 343 357 16394250
   PubMedGoogle Scholar
• Gruber C Gruber D Bazedoxifene (Wyeth) Curr Opin Investig Drugs 2004 5 10 1086 1093
   PubMedGoogle Scholar
• Chandrasekaran A Ermer J McKeand W Bazedoxifene acetate metabolic disposition in healthy, postmenopausal women Clinical Pharmacology and Therapeutics 2003 73 47
   Web of Science ®Google Scholar
• Chandrasekaran A McKeand WE Sullivan P DeMaio W Stoltz R Scatina J Metabolic disposition of [14C]bazedoxifene in healthy postmenopausal women Drug Metab Dispos 2009 37 6 1219 1225 19273530
   PubMed Web of Science ®Google Scholar
• Miller CP Collini MD Tran BD Design, synthesis, and preclinical characterization of novel, highly selective indole estrogens J Med Chem 2001 44 11 1654 1657 11356100
   PubMed Web of Science ®Google Scholar
• Ronkin S Northington R Baracat E Endometrial effects of bazedoxifene acetate, a novel selective estrogen receptor modulator, in postmenopausal women Obstet Gynecol 2005 6 105 1397 1404 15932835
   PubMed Web of Science ®Google Scholar
• Boudes P Ronkin S Korner P Effects of bazedoxifene TSE-424, a novel tissue selective estrogen receptor modulator SERM, on the incidence of breast pain [abstract] Osteoporos Int 2003 14 Suppl 7 S14
   Google Scholar
• Ronkin S Baracat E Roma L TSE-424, a novel tissue selective estrogen, reduces biochemical indices of bone metabolism in a dose related fashion Presented at: Endocrine Society 83rd Annual Meeting June 20–23, 2001 Denver, CO
   Google Scholar
• Miller PD Chines AA Christiansen C Effects of bazedoxifene on BMD and bone turnover in postmenopausal women: 2-yr results of a randomized, double-blind, placebo-, and active-controlled study J Bone Miner Res 2008 23 4 525 535 18072873
   PubMed Web of Science ®Google Scholar
• Silverman SL Christiansen C Genant HK Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial J Bone Miner Res 2008 23 12 1923 1934 18665787
   PubMed Web of Science ®Google Scholar
• Pinkerton JV Archer DF Utian WH Bazedoxifene effects on the reproductive tract in postmenopausal women at risk for osteoporosis Menopause 2009 16 6 1102 1108 19546825
   PubMed Web of Science ®Google Scholar
• Silverman SL Chines AA Kendler DL Bazedoxifene Study Group Sustained efficacy and safety of bazedoxifene in preventing fractures in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled study Osteoporos Int 2012 23 1 351 363 21779819
   PubMed Web of Science ®Google Scholar
• Palacios S Silverman S Levine AB Long-term efficacy and safety of bazedoxifene in postmenopausal women with osteoporosis: results of a 7-year, randomized, placebo-controlled study [abstract] Climacteric 2011 14 Suppl 1 59 60
   Google Scholar
• Bachmann G Crosby U Feldman RA Ronkin S Constantine GD Effects of bazedoxifene in nonflushing postmenopausal women: a randomized phase 2 trial Menopause 2011 18 5 508 514 21289525
   PubMed Web of Science ®Google Scholar
• Anderson GL Limacher M Assaf AR Women’s Health Initiative Steering Committee Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women’s Health Initiative randomized controlled trial JAMA 2004 291 14 1701 1712 15082697
   PubMed Web of Science ®Google Scholar
• Pickar JH Tissue selective estrogen complex: a new paradigm for menopausal therapy Menopausal Med 2008 16 1 S10 S13
   Google Scholar
• Pickar JH Yeh IT Bachmann G Speroff L Endometrial effects of a tissue selective estrogen complex containing bazedoxifene/conjugated estrogens as a menopausal therapy Fertil Steril 2009 92 3 1018 1024 19635613
   PubMed Web of Science ®Google Scholar
• Lobo RA Pinkerton JV Gass MLS Evaluation of bazedoxifene/conjugated estrogens for the treatment of menopausal symptoms and effects on metabolic bone parameters and overall safety profile Fertil Steril 2009 92 3 1025 1038 19635615
   PubMed Web of Science ®Google Scholar
• Archer DF Lewis V Carr BR Olivier S Pickar JH Bazedoxifene/conjugated estrogens (BZA/CE): incidence of uterine bleeding in postmenopausal women Fertil Steril 2009 92 3 1039 1044 19635614
   PubMed Web of Science ®Google Scholar
• Lindsay R Gallagher JC Kagan R Pickar JH Constantine G Efficacy of tissue-selective estrogen complex of bazedoxifene/conjugated estrogens for osteoporosis prevention in at-risk postmenopausal women Fertil Steril 2009 92 3 1045 1052 19635616
   PubMed Web of Science ®Google Scholar
• Pinkerton JV Utian WH Constantine GD Olivier S Pickar JH Relief of vasomotor symptoms with the tissue-selective estrogen complex containing bazedoxifene/conjugated estrogens: a randomized, controlled trial Menopause 2009 16 6 1116 1124 19546826
   PubMed Web of Science ®Google Scholar
• Kagan R Williams RS Pan K Mirkin S Pickar JH A randomized, placebo- and active-controlled trial of bazedoxifene/conjugated estrogens for treatment of moderate to severe vulvar/vaginal atrophy in postmenopausal women Menopause 2010 17 2 281 289 19779382
   PubMed Web of Science ®Google Scholar
• Mirkin S Komm BS Pan K Chines AA Effects of bazedoxifene/conjugated estrogens on endometrial safety and bone in postmenopausal women Climacteric 2013 16 3 338 346 23038989
   PubMed Web of Science ®Google Scholar
• Utian WH Shoupe D Bachmann G Pinkerton JV Pickar JH Relief of vasomotor symptoms and vaginal atrophy with lower doses of conjugated equine estrogens and medroxyprogesterone acetate Fertil Steril 2001 75 6 1065 1079 11384629
   PubMed Web of Science ®Google Scholar
• Pinkerton JV Chines AA Racketa J Mirkin S Bazedoxifene/conjugated estrogens (BZA/CE): effect on sleep parameters in postmenopausal women [abstract] Menopause 2010 17 6 1237 1238
   Web of Science ®Google Scholar
• Utian W Yu H Bobula J Mirkin S Olivier S Pickar JH Bazedoxifene/conjugated estrogens and quality of life in postmenopausal women Maturitas 2009 63 4 329 335 19647382
   PubMed Web of Science ®Google Scholar
• Pinkerton JV Chines AA Racketa J Mirkin S Menopause-related quality of life and satisfaction in postmenopausal women treated with bazedoxifene/conjugated estrogens (BZA/CE) [abstract] Menopause 2010 17 6 1219
   Web of Science ®Google Scholar
• Bachmann G Bobula J Mirkin S Effects of bazedoxifene/conjugated estrogens on quality of life in postmenopausal women with symptoms of vulvar/vaginal atrophy Climacteric 2010 13 2 132 140 19863455
   PubMed Web of Science ®Google Scholar
• Spencer CP Godsland IF Stevenson JC Is there a menopausal metabolic syndrome? Gynecol Endocrinol 1997 11 5 341 355 9385535
   PubMed Web of Science ®Google Scholar
• Adami S Rossini M Zamberlan N Bertoldo F Dorizzi R Lo Cascio V Long-term effects of transdermal and oral estrogens on serum lipids and lipoproteins in postmenopausal women Maturitas 1993 17 3 191 196 8133793
   PubMed Web of Science ®Google Scholar
• Maclennan AH Broadbent JL Lester S Moore V Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes Cochrane Database Syst Rev 2004 4 CD002978 15495039
   PubMedGoogle Scholar
• Smith DC Prentice R Thompson DJ Hermann WL Association of exogenous estrogen and endometrial carcinoma N Engl J Med 1975 293 23 1164 1167 1186789
   PubMed Web of Science ®Google Scholar
• Anderson GL Chlebowski RT Rossouw JE Prior hormone therapy and breast cancer risk in the Women’s Health Initiative randomized trial of estrogen plus progestin Maturitas 2006 55 2 103 115 16815651
   PubMed Web of Science ®Google Scholar
• Lindsay R Gallagher JC Kleerekoper M Pickar JH Effect of lower doses of conjugated equine estrogens with and without medroxyprogesterone acetate on bone in early postmenopausal women JAMA 2002 287 20 2668 2676 12020302
   PubMed Web of Science ®Google Scholar
• Adami S Bianchi G Brandi ML BONTURNO study group Determinants of bone turnover markers in healthy premenopausal women Calcif Tissue Int 2008 82 5 341 347 18470550
   PubMed Web of Science ®Google Scholar
• Bauer DC Black DM Garnero P Fracture Intervention Trial Study Group Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: the fracture intervention trial J Bone Miner Res 2004 19 8 1250 1258 15231011
   PubMed Web of Science ®Google Scholar
• Eastell R Barton I Hannon RA Chines A Garnero P Delmas PD Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate J Bone Miner Res 2003 18 6 1051 1056 12817758
   PubMed Web of Science ®Google Scholar
• Rossini M Orsolini G Adami S Kunnathully V Gatti D Osteoporosis treatment: why ibandronic acid? Expert Opin Pharmacother 2013 14 10 1371 1381 23650954
   PubMed Web of Science ®Google Scholar
• Rossini M Bianchi G Di Munno O Treatment of Osteoporosis in clinical Practice (TOP) Study Group Determinants of adherence to osteoporosis treatment in clinical practice Osteoporos Int 2006 17 6 914 921 16538553
   PubMed Web of Science ®Google Scholar